SK Biopharmaceuticals, SK and U.S. electronic drug company ‘Color Health’ jointly invested

Facebook
Twitter
LinkedIn
Pinterest
Pocket
WhatsApp

SK Biopharmaceuticals (CEO Jo Jung-woo) announced on the 19th that it will make a joint investment in ‘Cala Health’, an American electronic drug company, with SK, an investment company.

Starting with this investment, SK Biopharmaceuticals plans to continue strategic investments in high-tech pharmaceutical, bio, and healthcare companies.

Carla, an electronic drug company located in Silicon Valley, launched the world’s only ‘non-invasive electrical stimulation essential tremor’ treatment device in 2019. In addition, it has wearable platform technology that can be applied to the treatment of neurological and mental disorders and a sales network across the United States.

As a strategic investor (SI), SK Biopharmaceuticals is also exploring the possibility of technological cooperation in the field of color and brain science. Since 2018, SK Biopharmaceuticals has been conducting research and development of epilepsy seizure detection and prediction algorithms and devices, and is concurrently carrying out external collaboration and investment.

In particular, in the case of an epilepsy seizure detection device, domestic clinical trials are scheduled to begin this year, and it aims to present at the Consumer Electronics Show (CES) next year.

Renee Ryan, president of Carla Hell, said, “We are delighted that SK Biopharmaceuticals, a global pharmaceutical and biotech company, will participate in Carla’s investment. will,” he said.

SK Biopharmaceuticals CEO Jo Jung-woo said, “We will continue to secure innovative technologies by implementing various open innovations such as strategic investments in the future. We will be reborn as a solution company.”

Read Also  Hong Kong Stock Market: Hang Seng closed up 122.40 points | RYT9
Facebook
Twitter
LinkedIn
Pinterest
Pocket
WhatsApp

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Recent News

Editor's Pick